Showing 1 - 3 of 3
Persistent link: https://www.econbiz.de/10010360871
Without changes in the current policies, pharmaceutical companies will eventually cease responding to the incentives to develop orphan drugs, because they will increasingly be uncertain whether the drugs, if developed, will be reimbursed. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014
Persistent link: https://www.econbiz.de/10010993990
Persistent link: https://www.econbiz.de/10014328179